Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Diffuse Intrinsic Pontine Glioma 1Cut-Off Value 1Carcinosarcoma 1Carcinoma, Endometrioid 1Breast Neoplasms 1Breast Cancer Lymphedema 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Dexamethasone 238Lenalidomide 145daratumumab 123Bortezomib 101pomalidomide 86Calcium Dobesilate 76carfilzomib 74Cyclophosphamide 70Specimen Handling 42isatuximab 40Biopsy 40fludarabine 36belantamab mafodotin 36Magnetic Resonance Spectroscopy 35talquetamab 29dexamethasone acetate 27dexamethasone 21-phosphate 27Melphalan 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Fluid Therapy × 1 year × Clear all
NCT05847569 2026-02-03

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Mayo Clinic

Phase 2 Recruiting
62 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡